Table 1.
Characteristics of patients with cervical adenocarcinoma or squamous cell carcinoma who received curative surgery
| AJCC pathologic stages I-IIA | AJCC pathologic stages IIB-IVA | ||||||
|---|---|---|---|---|---|---|---|
|
|
|
||||||
| SCC (N = 2790) | Adenocarcinoma (N = 788) | P-value | SCC (N = 798) | Adenocarcinoma (N = 252) | P-value | ||
|
|
|
||||||
| n (%) | n (%) | n (%) | n (%) | ||||
| Age, years | Mean (SD) | 51.3 (12.3) | 48.6 (10.2) | <.0001 | 55.1 (11.8) | 51.5 (10.4) | <.0001 |
| Median (IQR: Q1, Q3) | 51 (20, 90) | 48 (25, 83) | 54 (24, 88) | 52 (27, 83) | |||
| Age group | 20-39 | 508 (18.2) | 138 (17.5) | <.0001 | 73 (9.1) | 31 (12.3) | .0015 |
| 40-49 | 772 (27.7) | 304 (38.6) | 167 (20.9) | 70 (27.8) | |||
| 50-59 | 811 (29.1) | 235 (29.8) | 296 (37.1) | 91 (36.1) | |||
| 60-69 | 475 (17.0) | 86 (10.9) | 164 (20.6) | 49 (19.4) | |||
| 70+ | 224 (8.0) | 25 (3.2) | 98 (12.3) | 11 (4.4) | |||
| Year of diagnosis | 2007-2009 | 1106 (39.6) | 265 (33.6) | .0085 | 306 (38.3) | 71 (28.2) | .0129 |
| 2010-2012 | 945 (33.9) | 298 (37.8) | 279 (35.0) | 105 (41.7) | |||
| 2013-2015 | 739 (26.5) | 225 (28.6) | 213 (26.7) | 76 (30.2) | |||
| FIGO stages | I-IIA | 2764 (99.1) | 780 (99.0) | .8314 | 630 (78.9) | 185 (73.4) | .0661 |
| IIB-IVA | 26 (0.9) | 8 (1.0) | 168 (21.1) | 67 (26.6) | |||
| AJCC pathologic stage | I | 2594 (93.0) | 744 (94.4) | .1532 | |||
| IIA | 196 (7.0) | 44 (5.6) | |||||
| IIIB | 199 (24.9) | 28 (11.1) | <.0001 | ||||
| IVA | 515 (64.5) | 167 (66.3) | |||||
| 4 | 84 (10.5) | 57 (22.6) | |||||
| Grade | I (well differentiated) | 149 (5.3) | 237 (30.1) | <.0001 | 21 (2.6) | 40 (15.9) | <.0001 |
| II (moderately differentiated) | 1287 (46.1) | 332 (42.1) | 512 (64.2) | 133 (52.8) | |||
| III (poorly differentiated) | 449 (16.1) | 98 (12.4) | 174 (21.8) | 56 (22.2) | |||
| IV (undifferentiated) | 9 (0.3) | 6 (0.8) | 3 (0.4) | 5 (2.0) | |||
| Missing | 896 (32.1) | 115 (14.6) | 88 (11.0) | 18 (7.1) | |||
| Surgical margin | No residual | 2457 (88.1) | 725 (92.0) | <.0001 | 590 (73.9) | 185 (73.4) | .3999 |
| Residual | 179 (6.4) | 19 (2.4) | 137 (17.2) | 50 (19.8) | |||
| Unknown | 154 (5.5) | 44 (5.6) | 71 (8.9) | 17 (6.7) | |||
| Adjuvant treatment | Adjuvant CCRT | 179 (6.4) | 71 (9.0) | .0080 | 408 (51.1) | 120 (47.6) | .0126 |
| Adjuvant sequential CT and RT | 24 (0.9) | 14 (1.8) | 53 (6.6) | 33 (13.1) | |||
| Adjuvant RT | 339 (12.2) | 97 (12.3) | 164 (20.6) | 51 (20.2) | |||
| No adjuvant | 2248 (80.6) | 606 (76.9) | 173 (21.7) | 48 (19.0) | |||
| RT cumulative dose, Gy | Mean (SD) | 45.8 (11.6) | 45.9 (11.7) | .9971 | 48.8 (14.9) | 48.8 (15.4) | .4020 |
| Median (IQR: Q1, Q3) | 50 (37, 56) | 50 (36, 56) | 50 (37, 56) | 50 (37, 56) | |||
| EBRT cumulative dose | No EBRT | 2272 (81.4) | 620 (78.7) | .2146 | 226 (28.3) | 81 (32.1) | .4015 |
| <50 Gy | 250 (9.0) | 83 (10.5) | 247 (31.0) | 79 (31.3) | |||
| 50+ Gy | 268 (9.6) | 85 (10.8) | 325 (40.7) | 92 (36.5) | |||
| Platinum cumulative dose, MG | Mean (SD) | 446.0 (224.3) | 533.2 (428.8) | .5141 | 488.4 (317.0) | 628.3 (614.7) | .1517 |
| Median (IQR: Q1, Q3) | 420 (300, 600) | 420 (300, 600) | 450 (300, 600) | 500 (300, 600) | |||
| Platinum cumulative dose | No CT | 2587 (92.7) | 703 (89.2) | .0058 | 337 (42.2) | 99 (39.3) | .5886 |
| <500 MG | 115 (4.1) | 47 (6.0) | 239 (29.9) | 75 (29.8) | |||
| 500+ MG | 88 (3.2) | 38 (4.8) | 222 (27.8) | 78 (31.0) | |||
| Intracavitary brachytherapy dose, cGy | Mean (SD) | 2275.2 (943.9) | 2213.7 (794.8) | .3015 | 2043.2 (812.6) | 2267.2 (753.3) | .8284 |
| Median (IQR: Q1, Q3) | 2500 (1500, 3000) | 2000 (1500, 2500) | 2000 (1500, 3000) | 2000 (1500, 2500) | |||
| Intracavitary brachytherapy dose | No intracavitary brachytherapy | 2167 (77.7) | 614 (77.9) | .3963 | 241 (30.2) | 89 (35.3) | .3123 |
| <2500 cGy | 490 (17.6) | 145 (18.4) | 454 (56.9) | 133 (52.8) | |||
| 2500+ cGy | 133 (4.8) | 29 (3.7) | 103 (12.9) | 30 (11.9) | |||
| CCI Score | Mean (SD) | 0.3 (0.7) | 0.3 (0.7) | .1054 | 0.3 (0.7) | 0.4 (0.8) | .2343 |
| 0 | 2216 (79.4) | 647 (82.1) | .2362 | 637 (79.8) | 192 (76.2) | .4216 | |
| 1 | 396 (14.2) | 95 (12.1) | 105 (13.2) | 41 (16.3) | |||
| 2+ | 178 (6.4) | 46 (5.8) | 56 (7.0) | 19 (7.5) | |||
| Income | <NTD 18,000 | 695 (24.9) | 148 (18.8) | .0002 | 218 (27.3) | 62 (24.6) | .5471 |
| NTD 18,000-22,500 | 995 (35.7) | 283 (35.9) | 266 (33.3) | 82 (32.5) | |||
| NTD 22,500-30,000 | 398 (14.3) | 108 (13.7) | 118 (14.8) | 35 (13.9) | |||
| NTD 30,000+ | 702 (25.2) | 249 (31.6) | 196 (24.6) | 73 (29.0) | |||
| Hospital level | Medical center | 1950 (69.9) | 579 (73.5) | .0509 | 509 (63.8) | 186 (73.8) | .0034 |
| Other | 840 (30.1) | 209 (26.5) | 289 (36.2) | 66 (26.2) | |||
| Hospital area | North | 1388 (49.7) | 435 (55.2) | .0238 | 332 (41.6) | 130 (51.6) | .0003 |
| Middle | 601 (21.5) | 147 (18.7) | 141 (17.7) | 55 (21.8) | |||
| South/East | 801 (28.7) | 206 (26.1) | 325 (40.7) | 67 (26.6) | |||
| Mean follow-up time, months (SD) | 79.5 (31.8) | 75.0 (31.1) | 66.2 (35.4) | 46.0 (31.0) | |||
| Death | 206 (7.38) | 79 (10.03) | 245 (30.70) | 143 (56.75) | |||
| Local recurrence | 207 (7.42) | 52 (6.60) | 94 (11.78) | 38 (15.08) | |||
| Distant metastasis | 103 (3.69) | 68 (8.63) | 180 (22.56) | 91 (36.11) | |||
CCRT, concurrent chemoradiotherapy; cGy, centigray; Gy, gray; SCC, squamous cell carcinoma; FIGO, International Federation of Gynecology and Obstetrics; CT, chemotherapy; RT, radiotherapy; EBRT, external beam radiotherapy; CCI, Charlson comorbidity index; MG, milligrams; SD, standard deviation; IQR, interquartile range; NTD, New Taiwan dollar, AJCC, American Joint Committee on Cancer.